8.25
+0.61%
Close of 9 Nov 2026, in AUD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Anteris Technologies Global
Its shares trade on ASX under the ticker AVR.AX. It has been listed since 24 March 2004. In the fiscal year to 31 December 2025, it reported revenue of $1.9m and a net loss of $94.0m. At that date it held total assets of $23.0m and shareholders' equity of −$90,000.
Anteris Technologies Ltd. is engaged in the development, commercialization, and distribution of medical products and technologies. The company is headquartered in Toowong, Queensland. The company went IPO on 2004-03-24. The firm provides solutions for heart valves. Its products include ADAPT and DurAVR. ADAPT its anti-calcification treatment platform technology on which its structural heart products are developed. DurAVR, built with ADAPT technology, is a durable three dimension (3D) single-piece aortic valve for the treatment of aortic stenosis. Its DurAVR Development Portfolio includes DurAVR Leaflet Repair (RP), DurAVR Transcatheter Heart Valve (THV) and DurAVR Surgical Heart Valve (SHV).
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Health Care Equipment & Supplies
- Listed since
- 24 Mar 2004
- Employees
- 1
- Website
- anteristech.com ↗
Leadership
Pay as last reported
- Mr. John SeabergNon-Executive Independent Chairman of the BoardA$723,057
- Mr. Wayne PatersonChief Executive Officer, Managing Director, Executive Director, since 2014A$3.6m
- Mr. Matthew McdonnellChief Financial OfficerA$826,007
- Mr. David St. DenisChief Operating OfficerA$1.7m
- Dr. Chris MeduriChief Medical Officer
- Mr. Stephen DenaroCompany Secretary, Non-Executive Independent DirectorA$420,521
- Dr. Wenyi GuNon-Executive DirectorA$366,467
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Anteris Technologies Ltd possesses several strengths that contribute to its success in the market. The company has a strong portfolio of innovative medical technologies and products, which gives it a competitive edge. Additionally, their extensive research and development capabilities enable them to continuously create new solutions and stay ahead of the curve.
Weaknesses
- Despite its strengths, Anteris Technologies Ltd also faces a few weaknesses that it needs to address. One weakness is the company's heavy reliance on a limited number of key clients for revenue generation, which poses a potential risk if there are any disruptions in these partnerships. Another weakness is the lack of diversified product offerings, making them vulnerable to market fluctuations in certain segments.
Opportunities
- Anteris Technologies Ltd has identified several opportunities that could fuel its growth. The increasing demand for advanced medical technologies and solutions presents a significant growth opportunity for the company. By expanding into new geographical markets and forging strategic partnerships, Anteris can tap into untapped markets and expand its customer base. Additionally, the growing focus on healthcare advancements and investment in medical research offers opportunities for collaboration and product development.
Threats
- Like any company, Anteris Technologies Ltd also faces potential threats that may impact its business. One major threat is competitive pressure from larger and more established players in the medical technology industry. Additionally, regulatory changes and compliance requirements pose a risk, as non-compliance could result in penalties and delays in product launches. Market volatility and economic uncertainties can also impact customer spending, affecting the demand for Anteris' products and services.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.